CLINUVEL PHARMACEUTICALS LTD (Seite 1925)

[printguru]

So schwach wie der Gesamtmarkt zur Zeit dasteht sollte das möglich sein.

LG Printi

[printguru]

Antwort auf Beitrag Nr.: 57.205.645 von -Morpheus- am 06.03.18 21:52:46

Hallo Morpheus

klingt erstmal Alles sehr interessant sollte ich einsteigen werde ich versuchen um die 5-5,1€ reinzukommen.


LG Printi

[-Morpheus-]

Antwort auf Beitrag Nr.: 57.205.597 von walltrader2014 am 06.03.18 21:47:20

Bei NICE ist es einfach das angeschlagene Gesundheitssystem in UK. @printguru: Willkommen im Forum

[walltrader2014]

Ich sehe das mit der NICE nicht so schlimm. Je mehr Patienten Clinuvel in anderen europäische Ländern findet und behandelt, desto mehr können sie auch mit dem Preis runtergehen. Irgendwann wird die NICE schon zustimmen

[10-bagger]

Antwort auf Beitrag Nr.: 57.204.742 von printguru am 06.03.18 20:27:31

klingt zu pessimistisch, 40-50 millionen aud umsatz sind absolut realistisch für 2018, sphene capital schätzt 46,2 ablehnung durch nice ist inkludiert.

[-Morpheus-]

Man hat das Gefühl an der Börse steht gerade alles still. Ein paar Punkte +, ein paar Punkte -

[walltrader2014]

Antwort auf Beitrag Nr.: 57.205.132 von printguru am 06.03.18 21:02:23

printguru, das ist ein alter Beitrag! Inzwischen hat sich bei Clinuvel viel geändert, z.B. gibt es für die Scenesse Behandlung in Düsseldorf einen zusätzlichen Arzt.

Orientier dich am besten an dem aktuellen Researchreport von Sphene Capital:

http://www.equitystory.com/Download/Research/Clinuvel_Initia…

[printguru]

Antwort auf Beitrag Nr.: 57.205.069 von emittex am 06.03.18 20:56:55

https://hotcopper.com.au/threads/ann-scenesse-treatment-in-e…

[emittex]

Antwort auf Beitrag Nr.: 57.204.742 von printguru am 06.03.18 20:27:31

Zitat von printguru: was haltet ihr von diesem Posting


18 months ago when the price of the implant was discovered I made some predictions regarding expected sales and share price.
Since then the share price has almost doubled so I am not riddled with guilt if anyone bought on the strength of my post however it has not proceeded as I had hoped for. Nothing ever does!

The German rollout has been, and remains an issue. Pricing negotiations were “difficult” however ultimately successful but much more unexpected was the log jam encountered at the doctor patient level. With patients being turned away due to lack of resources, this has resulted in a much slower take up in the largest non US market. This is expected to only slowly resolve over the foreseeable future tempering revenue expectations.

UK was expected to be done and dusted without incident. The HST/STA/HST debacle cost time with NICE recently delivering a negative preliminary assessment. Clinuvel’s second biggest market outside of the US is seemingly no closer to reimbursement also tempering expectations.

Switzerland, proceeded in the courts with Clinuvel escaping with a bloody nose and damaged reputation having been tarnished with the greedy pharma brush. A problem which seemingly could have been avoided with Swissmedic approval.

Italy has been slow to adopt the new price and some concessions by Clinuvel were given with an agreement to pay for the screening required as part of the EMA dictated post approval safety study.

Austria seems to be treating patients in the single digits and is of little consequence.

Holland is the shining light, with over 100 patients receiving treatment paying full price.

There remains no news from other EU countries or Norway. Wolgen in the AR has reported that a further 6 countries will be targeted in 2018. This has been perhaps disappointing. 5 US patients travel to Switzerland to receive the implant at an unknown price, this is subsidised by US insurance.

What is extremely positive is the reported rate of re-treatment with over 90% of treated patients re-attending for treatment in the second year. This is consistent with the long term data from Switzerland and Italy where the numbers actually increased over the 8 year observation period. This is outstanding for any intervention that treats a symptom only.

I was hopeful of a revenue of $100 million this year, 2018 with over 1000 patients being treated. Last year it was 17 million and with the issues discussed (no UK patients, very few in Germany) clearly Clinuvel wont get anywhere near 100 million this year. $5.5 million in the first quarter with reduced revenues expected for the next 2 quarters, maybe $20-25 million revenue this year. Expenses should be reasonably stable at 9 million. My predicted PE of 50 seems to be about right so a market cap of around 550 - 800 million is still achievable and reasonable IMO, share price $11 - $16. Still plenty of upside and limited downside.




5

Like


 Great analysis


Report Post


Bookmark and Share

CUV (ASX)
Price at posting: $9.10
Sentiment: Buy
Disclosure: Held


https://hotcopper.com.au/threads/ann-scenesse-treatment-in-e…

Wie bist Du nun da drauf gestoßen?
Post von 2016....?

[printguru]

Antwort auf Beitrag Nr.: 57.204.598 von walltrader2014 am 06.03.18 20:15:44

danke

LG Printi